 Giulia Baldini
Concepts (202)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, Melanocortin, Type 4 | 10 | 2024 | 19 | 4.000 |
Why?
| | Neurons | 8 | 2024 | 418 | 2.540 |
Why?
| | Hypothalamus | 5 | 2024 | 44 | 1.880 |
Why?
| | alpha-MSH | 6 | 2019 | 17 | 1.830 |
Why?
| | Cell Membrane | 8 | 2017 | 245 | 1.450 |
Why?
| | Endoplasmic Reticulum | 6 | 2013 | 114 | 1.440 |
Why?
| | Pro-Opiomelanocortin | 3 | 2019 | 9 | 0.830 |
Why?
| | Mice | 15 | 2024 | 5965 | 0.790 |
Why?
| | Paraventricular Hypothalamic Nucleus | 2 | 2019 | 9 | 0.780 |
Why?
| | Metformin | 1 | 2022 | 76 | 0.740 |
Why?
| | alpha 1-Antitrypsin | 3 | 2011 | 15 | 0.730 |
Why?
| | Obesity | 5 | 2019 | 1162 | 0.720 |
Why?
| | Endocytosis | 3 | 2017 | 55 | 0.700 |
Why?
| | Appetite | 2 | 2019 | 15 | 0.690 |
Why?
| | Cyclic AMP | 4 | 2015 | 91 | 0.690 |
Why?
| | Clathrin | 2 | 2017 | 5 | 0.660 |
Why?
| | Melanocortins | 1 | 2019 | 3 | 0.630 |
Why?
| | Animals | 19 | 2024 | 13523 | 0.620 |
Why?
| | Agouti-Related Protein | 2 | 2015 | 3 | 0.600 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 44 | 0.600 |
Why?
| | Protein Conformation | 3 | 2015 | 179 | 0.580 |
Why?
| | Inclusion Bodies | 2 | 2008 | 17 | 0.570 |
Why?
| | Repressor Proteins | 1 | 2019 | 156 | 0.560 |
Why?
| | Hyperlipidemias | 1 | 2017 | 52 | 0.540 |
Why?
| | Diet, High-Fat | 1 | 2019 | 237 | 0.520 |
Why?
| | Signal Transduction | 3 | 2019 | 1716 | 0.500 |
Why?
| | Peptides, Cyclic | 1 | 2015 | 42 | 0.480 |
Why?
| | Autophagy | 4 | 2012 | 197 | 0.480 |
Why?
| | Mutation, Missense | 2 | 2013 | 108 | 0.460 |
Why?
| | Appetite Regulation | 1 | 2013 | 12 | 0.430 |
Why?
| | Protein Folding | 3 | 2012 | 61 | 0.430 |
Why?
| | Mutation | 5 | 2014 | 1351 | 0.420 |
Why?
| | Nerve Tissue Proteins | 3 | 2004 | 193 | 0.390 |
Why?
| | Membrane Proteins | 3 | 2004 | 340 | 0.380 |
Why?
| | Activating Transcription Factor 6 | 1 | 2011 | 16 | 0.370 |
Why?
| | Exocytosis | 4 | 2006 | 12 | 0.370 |
Why?
| | Mutant Proteins | 2 | 2010 | 37 | 0.370 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2011 | 200 | 0.370 |
Why?
| | Cell Line | 5 | 2017 | 1045 | 0.370 |
Why?
| | Cholesterol | 1 | 2012 | 156 | 0.370 |
Why?
| | Mitochondria, Liver | 1 | 2011 | 69 | 0.360 |
Why?
| | Phagosomes | 2 | 2008 | 19 | 0.360 |
Why?
| | Protein Transport | 4 | 2015 | 183 | 0.350 |
Why?
| | Phenylbutyrates | 1 | 2010 | 2 | 0.340 |
Why?
| | Cytoplasmic Granules | 2 | 2016 | 21 | 0.320 |
Why?
| | Neoplasm Proteins | 1 | 2011 | 334 | 0.310 |
Why?
| | Palmitates | 2 | 2022 | 29 | 0.310 |
Why?
| | Lysosomes | 3 | 2017 | 78 | 0.310 |
Why?
| | Endoplasmic Reticulum Stress | 2 | 2022 | 50 | 0.300 |
Why?
| | Cytoprotection | 1 | 2007 | 33 | 0.290 |
Why?
| | Unfolded Protein Response | 3 | 2014 | 33 | 0.280 |
Why?
| | Calcium | 3 | 2004 | 375 | 0.280 |
Why?
| | Cell Line, Tumor | 5 | 2011 | 1436 | 0.270 |
Why?
| | Microscopy, Fluorescence | 3 | 2015 | 149 | 0.270 |
Why?
| | Peptides | 2 | 2019 | 229 | 0.250 |
Why?
| | Calcium-Binding Proteins | 2 | 2004 | 57 | 0.250 |
Why?
| | rab3 GTP-Binding Proteins | 1 | 2005 | 1 | 0.240 |
Why?
| | Actinin | 1 | 2005 | 4 | 0.240 |
Why?
| | Cytoskeleton | 1 | 2005 | 39 | 0.240 |
Why?
| | Green Fluorescent Proteins | 3 | 2015 | 89 | 0.230 |
Why?
| | Actins | 1 | 2005 | 117 | 0.230 |
Why?
| | Membrane Glycoproteins | 2 | 2004 | 244 | 0.230 |
Why?
| | Cells, Cultured | 3 | 2024 | 1589 | 0.220 |
Why?
| | Synapses | 1 | 2024 | 74 | 0.220 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2024 | 79 | 0.220 |
Why?
| | Receptors, Transferrin | 2 | 2017 | 16 | 0.210 |
Why?
| | Mitochondria | 2 | 2022 | 428 | 0.200 |
Why?
| | Apoptosis | 2 | 2022 | 1127 | 0.190 |
Why?
| | Vesicular Transport Proteins | 1 | 2002 | 38 | 0.190 |
Why?
| | Wrist | 1 | 2022 | 15 | 0.190 |
Why?
| | Vincristine | 1 | 2022 | 88 | 0.190 |
Why?
| | Prostheses and Implants | 1 | 2022 | 55 | 0.190 |
Why?
| | Ubiquitination | 2 | 2012 | 57 | 0.180 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 91 | 0.180 |
Why?
| | Equipment Design | 1 | 2022 | 284 | 0.180 |
Why?
| | Microscopy, Confocal | 2 | 2015 | 84 | 0.170 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2012 | 1377 | 0.160 |
Why?
| | Anti-Obesity Agents | 1 | 2019 | 17 | 0.160 |
Why?
| | Gene Expression | 2 | 2014 | 623 | 0.150 |
Why?
| | Protein Structure, Tertiary | 3 | 2004 | 252 | 0.150 |
Why?
| | CTLA-4 Antigen | 1 | 2017 | 23 | 0.140 |
Why?
| | Histone Code | 1 | 2017 | 32 | 0.140 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 41 | 0.130 |
Why?
| | Transfection | 3 | 2012 | 372 | 0.130 |
Why?
| | Humans | 13 | 2022 | 52336 | 0.130 |
Why?
| | Recombinant Fusion Proteins | 2 | 2010 | 179 | 0.130 |
Why?
| | Cytoplasm | 1 | 2016 | 97 | 0.130 |
Why?
| | Photobleaching | 1 | 2015 | 1 | 0.120 |
Why?
| | Adenylate Kinase | 1 | 2015 | 10 | 0.120 |
Why?
| | Tetrahydroisoquinolines | 1 | 2015 | 9 | 0.120 |
Why?
| | Microscopy, Immunoelectron | 3 | 2005 | 11 | 0.120 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2015 | 17 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2015 | 33 | 0.120 |
Why?
| | G-Quadruplexes | 1 | 2016 | 77 | 0.120 |
Why?
| | Triazoles | 1 | 2015 | 115 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 327 | 0.110 |
Why?
| | DNA Damage | 1 | 2016 | 307 | 0.110 |
Why?
| | 5'-Nucleotidase | 1 | 2014 | 12 | 0.110 |
Why?
| | Protein Biosynthesis | 1 | 2016 | 265 | 0.110 |
Why?
| | Melanoma | 1 | 2017 | 280 | 0.110 |
Why?
| | Dyslipidemias | 1 | 2014 | 42 | 0.110 |
Why?
| | Immunoenzyme Techniques | 1 | 2013 | 137 | 0.110 |
Why?
| | Syntaxin 1 | 2 | 2004 | 3 | 0.110 |
Why?
| | R-SNARE Proteins | 2 | 2004 | 9 | 0.100 |
Why?
| | Synaptotagmins | 2 | 2004 | 4 | 0.100 |
Why?
| | Antigens, Surface | 2 | 2004 | 47 | 0.100 |
Why?
| | Antibodies, Monoclonal | 1 | 2017 | 481 | 0.100 |
Why?
| | Protein Binding | 2 | 2005 | 680 | 0.100 |
Why?
| | Synaptosomal-Associated Protein 25 | 2 | 2002 | 4 | 0.100 |
Why?
| | RNA, Messenger | 1 | 2016 | 1142 | 0.100 |
Why?
| | Homeostasis | 2 | 2012 | 206 | 0.100 |
Why?
| | Analysis of Variance | 1 | 2013 | 555 | 0.100 |
Why?
| | Threonine | 1 | 2012 | 15 | 0.100 |
Why?
| | Serine | 1 | 2012 | 36 | 0.100 |
Why?
| | Endosomes | 1 | 2012 | 36 | 0.100 |
Why?
| | Biological Assay | 1 | 2012 | 47 | 0.100 |
Why?
| | Transcription Factor CHOP | 1 | 2011 | 7 | 0.090 |
Why?
| | CCAAT-Enhancer-Binding Proteins | 1 | 2011 | 14 | 0.090 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2012 | 57 | 0.090 |
Why?
| | Proteins | 1 | 2015 | 354 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 218 | 0.090 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 82 | 0.090 |
Why?
| | Oxidative Stress | 1 | 2016 | 810 | 0.090 |
Why?
| | HEK293 Cells | 1 | 2012 | 232 | 0.090 |
Why?
| | DNA Fragmentation | 1 | 2011 | 55 | 0.090 |
Why?
| | Proteolysis | 1 | 2011 | 102 | 0.090 |
Why?
| | COS Cells | 2 | 2014 | 85 | 0.090 |
Why?
| | Cell Size | 2 | 2007 | 48 | 0.080 |
Why?
| | Male | 4 | 2019 | 26696 | 0.080 |
Why?
| | Time Factors | 2 | 2007 | 2957 | 0.080 |
Why?
| | Serpins | 1 | 2007 | 5 | 0.070 |
Why?
| | Calnexin | 1 | 2007 | 5 | 0.070 |
Why?
| | Protein Disulfide-Isomerases | 1 | 2007 | 14 | 0.070 |
Why?
| | Neurites | 1 | 2007 | 14 | 0.070 |
Why?
| | Neuropeptides | 1 | 2007 | 37 | 0.070 |
Why?
| | Neuroblastoma | 1 | 2007 | 51 | 0.070 |
Why?
| | Clathrin-Coated Vesicles | 1 | 2006 | 4 | 0.070 |
Why?
| | Retinoblastoma | 1 | 2006 | 15 | 0.070 |
Why?
| | Cell Line, Transformed | 1 | 2006 | 75 | 0.070 |
Why?
| | Models, Biological | 2 | 2012 | 743 | 0.060 |
Why?
| | PC12 Cells | 1 | 2005 | 25 | 0.060 |
Why?
| | Cytosol | 1 | 2005 | 81 | 0.060 |
Why?
| | Immunoblotting | 1 | 2005 | 119 | 0.060 |
Why?
| | Glutathione Transferase | 1 | 2005 | 176 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2005 | 191 | 0.060 |
Why?
| | Energy Metabolism | 1 | 2006 | 306 | 0.060 |
Why?
| | Precipitin Tests | 1 | 2004 | 34 | 0.050 |
Why?
| | Qb-SNARE Proteins | 1 | 2004 | 6 | 0.050 |
Why?
| | Qc-SNARE Proteins | 1 | 2004 | 10 | 0.050 |
Why?
| | Subcellular Fractions | 1 | 2004 | 34 | 0.050 |
Why?
| | Luminescent Proteins | 1 | 2004 | 51 | 0.050 |
Why?
| | DNA, Complementary | 1 | 2004 | 137 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 291 | 0.050 |
Why?
| | Botulinum Toxins | 1 | 2002 | 3 | 0.050 |
Why?
| | Chromaffin Cells | 1 | 2002 | 1 | 0.050 |
Why?
| | Adrenal Medulla | 1 | 2002 | 5 | 0.050 |
Why?
| | Synaptotagmin I | 1 | 2002 | 2 | 0.050 |
Why?
| | Chromogranins | 1 | 2002 | 6 | 0.050 |
Why?
| | Chromogranin A | 1 | 2002 | 5 | 0.050 |
Why?
| | Membrane Fusion | 1 | 2002 | 10 | 0.050 |
Why?
| | Macrolides | 1 | 2002 | 17 | 0.050 |
Why?
| | SNARE Proteins | 1 | 2002 | 16 | 0.050 |
Why?
| | Genes, Reporter | 1 | 2002 | 88 | 0.050 |
Why?
| | Cysteine | 1 | 2002 | 50 | 0.050 |
Why?
| | Torque | 1 | 2022 | 16 | 0.050 |
Why?
| | Wrist Joint | 1 | 2022 | 11 | 0.050 |
Why?
| | Artificial Limbs | 1 | 2022 | 15 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 179 | 0.050 |
Why?
| | Microtubules | 1 | 2022 | 39 | 0.050 |
Why?
| | bcl-2-Associated X Protein | 1 | 2022 | 58 | 0.050 |
Why?
| | Caspase 3 | 1 | 2022 | 94 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2004 | 326 | 0.050 |
Why?
| | Mitosis | 1 | 2022 | 89 | 0.050 |
Why?
| | Hand | 1 | 2022 | 51 | 0.050 |
Why?
| | Rats | 2 | 2005 | 3202 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 456 | 0.050 |
Why?
| | Range of Motion, Articular | 1 | 2022 | 108 | 0.050 |
Why?
| | Enzyme Activation | 1 | 2022 | 272 | 0.050 |
Why?
| | Binding Sites | 1 | 2002 | 379 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 591 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 792 | 0.040 |
Why?
| | Cell Cycle | 1 | 2022 | 240 | 0.040 |
Why?
| | Female | 2 | 2019 | 28105 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2017 | 58 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 263 | 0.030 |
Why?
| | Proteome | 1 | 2017 | 170 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2017 | 340 | 0.030 |
Why?
| | GPI-Linked Proteins | 1 | 2014 | 32 | 0.030 |
Why?
| | Gene Frequency | 1 | 2012 | 99 | 0.020 |
Why?
| | Ubiquitin | 1 | 2012 | 68 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 180 | 0.020 |
Why?
| | Alleles | 1 | 2012 | 277 | 0.020 |
Why?
| | Child, Preschool | 1 | 2012 | 4030 | 0.010 |
Why?
| | Electrochemistry | 1 | 2002 | 24 | 0.010 |
Why?
| | Organelles | 1 | 2002 | 15 | 0.010 |
Why?
| | Potassium | 1 | 2002 | 56 | 0.010 |
Why?
| | Electric Stimulation | 1 | 2002 | 107 | 0.010 |
Why?
| | Cattle | 1 | 2002 | 207 | 0.010 |
Why?
| | Child | 1 | 2012 | 7157 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 985 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2002 | 1552 | 0.010 |
Why?
| | Anti-Bacterial Agents | 1 | 2002 | 801 | 0.010 |
Why?
|
|
Baldini's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|